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A B S T R A C T
Capillaroscopy is a non-invasive and safe tool which allows the evaluation of the morphology of the microcirculation. Since its recent incorporation in the 2013
American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for systemic sclerosis together with its assessed role
to monitor disease progression, capillaroscopy became a ‘mainstream’ investigation for rheumatologists. Given its increasing use by a variety of physicians inter-
nationally both in daily practice to differentiate primary from secondary Raynaud's phenomenon, as well as in research context to predict disease progression and
monitor treatment effects, standardisation in capillaroscopic image acquisition and analysis seems paramount. To step forward to this need, experts in the field of
capillaroscopy/microcirculation provide in this very consensus paper their view on image acquisition and analysis, different capillaroscopic techniques, normal and
abnormal capillaroscopic characteristics and their meaning, scoring systems and reliability of image acquisition and interpretation.
1. Introduction
Structural microvascular abnormalities are one of the key features
of systemic sclerosis (SSc) related to the pathophysiological process and
can be visualised non-invasively using the technique of nailfold ca-
pillaroscopy. This is because at the nailfold, capillaries run parallel
rather than perpendicular to the skin surface and so their structure can
be demonstrated [1]. Sometimes the capillaries are so abnormally al-
tered that they can be seen with the naked eye (see Fig. 1), although
magnification is usually required. The capillary walls themselves are
invisible: what is seen is the column of red blood cells within the ca-
pillary.
Nailfold capillaroscopy is now a ‘mainstream’ investigation for
rheumatologists, because (as discussed below) a “scleroderma pattern”
helps to differentiate primary from secondary Raynaud's phenomenon
(RP). “Abnormal nailfold capillaries” (when referring to the “scler-
oderma pattern”) are included in the 2013 American College of
Rheumatology (ACR)/ European League Against Rheumatism (EULAR)
classification criteria for SSc, scoring two points out of the nine re-
quired for classification [2,3].
With the increasing use of nailfold capillaroscopy internationally, it
is important to have consensus concerning methods of acquiring and
analysing nailfold capillaries, as well as having clarity concerning what
the terminology “abnormal” means. After giving a brief background to
the development of nailfold capillaroscopy as a diagnostic tool, this
paper gives a consensus view from experts in capillaroscopy/micro-
circulation on image acquisition and analysis, different capillaroscopic
techniques, normal and abnormal capillaroscopic characteristics and
their meaning, scoring systems and reliability of image acquisition and
interpretation.
2. Background and history
Readers interested in a full history of the development of ca-
pillaroscopy are referred to a chapter by Cutolo [4]. For rheumatolo-
gists, particularly for those with an interest in SSc, the story begins in
the 1970s, with the seminal work by Maricq et al. on capillaroscopy in
connective tissue diseases (CTDs) [5–7]. Maricq used a wide-field mi-
croscope (magnification in the order of 12×) which allows a view of
the whole nailfold. The key abnormalities of a “scleroderma pattern”
include widened capillaries, avascularity (“loop drop-out”), haemor-
rhages and distortion of the normal capillary architecture [5,6]. One of
the factors leading to increasing interest in capillaroscopy in the 1990s
was the development of high magnification videocapillaroscopy, which
typically uses magnifications in the order of 200×.
Since the 1990s, capillaroscopy has continued to gain momentum in
both clinical practice and research [8]. For the clinician, its main ap-
plication is early identification of an underlying scleroderma spectrum
(SDS) disorder in the patient presenting with RP [9–11]. Since 2004,
EULAR training courses have been held on alternate years and have
been oversubscribed, demonstrating the increased interest in ca-
pillaroscopy and training need. A recent survey amongst clinicians with
an interest in SSc demonstrated that most respondents used nailfold
Fig. 1. Non-magnified picture of an abnormal nailfold.
Non-magnified picture of an abnormal nailfold to show that specific abnorm-
alities can sometimes even be detected with the unassisted eye. More specifi-
cally, a specific abnormality of the following capillaroscopic characteristic:
“capillary dimension”, i.e. giant capillaries can be seen with the naked eye (⇓
“giants”).
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videocapillaroscopy (NVC) in their everyday clinical practice [12].
From the research perspective, increasing numbers of publications re-
flect a large number of different areas of research (see Fig. 2), including
associates of abnormal nailfold capillary characteristics; “scleroderma
patterns” as a predictor of disease (e.g. of digital ulceration) [13–15]
and reliability of image acquisition and interpretation [16–22]. Estab-
lishing reliability of different qualitative and quantitative nailfold
parameters is especially important if nailfold capillaroscopy is to be
used as an outcome measure in clinical trials (see “5. Scoring Systems”).
3. Capillaroscopy equipment
Different devices can be used to perform capillaroscopy, as it is an in
vivo imaging investigation that consists of a magnified view of the
structural aspects of the nailfold microcirculation. The commercially
available tools range from the wide-field microscope and videoca-
pillaroscope to smartphone devices and are characterized by different
portability, costs, training period and image quality (see Table 1). The
research tools will be discussed in section “5. Scoring Systems”.
In the seventies, Maricq described the presence of specific patho-
logic capillary abnormalities in patients with SDS disorders using wide-
field microscopy [5,6,23]. To this purpose, a photomicrography system,
made-up by a stereomicroscope connected with a reflex camera with
good optical resolution (photos were developed with 3-4× magnifica-
tion on the negative), was used [6]. This device is quite expensive and
needs a longer training time than other devices due to difficulties in
maintaining an optimal relationship between release times, field
lighting, the presence of micro-movements of the patient's hand and
reflections generated by the incidental light strip [5,6,23]. Nailfold
stereomicroscopy allows physicians to see the whole nailfold area al-
most in a single frame and it is useful for a quick panoramic view of the
entire microvascular network. The overall pattern is easily interpreted
because in the wide-field view, overt capillary abnormalities are con-
trasted with surrounding normal areas. By contrast, the wide-field view
cannot be easily used to analyse capillary details and apply measuring
features, even though quantitative seminal studies have been performed
(see also Supplementary File 1) [7,16].
Shortly thereafter, the ophthalmoscope has been proposed as an
everyday instrument to extend the use of nailfold capillaroscopy in
clinical practice [24,25]. Due to its low cost and good portability, it
may be available to all physicians at the bedside or in the clinic [25]. It
has been demonstrated that major capillary abnormalities related to
SDS disorders can be detected with both the ophthalmoscope and ste-
reomicroscope [26–28]. On the other hand, the ophthalmoscope is not
suitable for research purposes as images cannot be stored and analysed.
The dermatoscope, which is easier to use than the ophthalmoscope,
is considered an appropriate device to perform nailfold capillaroscopy
and is purchasable at reasonable cost [12]. Even though a higher per-
centage of images are not classifiable by the dermatoscope, the inter-
and intra-rater reliability are comparable to NVC [27,29–33]. Hence
experts agree it can be used to identify capillary abnormalities, which
may be corroborated in a second step by NVC (see Fig. 3). Also, re-
cently, nailfold dermatoscopy has been proposed as part of the rheu-
matology fellow curriculum in the USA [34].
Smartphones have an embedded digital camera that can be adapted
for capillaroscopy, via the use of an adapted dermatoscope or macro-
photography lens. Recently, the performance of the smartphone-der-
matoscope and smartphone-lens was tested [35]. Both tools are novel
and relatively inexpensive portable devices which performed accep-
tably, even in the hands of a novice. In this way they had a high spe-
cificity but a lower sensitivity than the wide-field microscope to discern
“non-scleroderma” from “scleroderma patterns” [35]. Of note, the
dermatoscope and the smartphone may be used as screening tools when
the gold standard, the NVC is not available.
Digital USB microscopy is considered another useful tool to perform
nailfold capillaroscopy, and the probe can be connected with a laptop
allowing image storage. Because of simplicity of the equipment the
training period is brief. The digital USB microscope can be used in
clinical practice, but not at present in a research setting because soft-
ware for measuring capillary density and dimensions is not commer-
cially available [12].
The gold standard device is the digital videocapillaroscope that
combines a microscope with a digital video camera. At this moment, it
is the only tool which has attested the ability to be trained in such a way
that capillaroscopists of any level of experience can classify images as
“scleroderma pattern” or not, as well as a principal expert [22]. The
high sensitivity of the camera and the co-axial illumination of the field
allow images of high-resolution quality to be obtained. Moreover, di-
gital filters such as grey scale, watershed and top-hat filters can be
applied to separate the relevant areas from image background. Mag-
nification can range between 50× and 500×, but the most used is the
200× magnification. The commercially available videocapillaroscope
is able to store and analyse each single frame separately. To have a
wider view of the nailfold area using frame registration, an innovative
Fig. 2. Number of articles published on nailfold capillaroscopy in rheumatic diseases.
Full articles published from 1970 to 2018 were retrieved from PubMed using the search word “nailfold capillaroscopy”. Only articles on rheumatic diseases are
represented in the graph.
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software that combines adjacent images has been designed in order to
build up a panoramic “mosaic” of the entire nailfold at 300× magni-
fication [36]. The videocapillaroscope is currently considered the most
appropriate device for clinical and research purposes [12]. However,
videocapillaroscopes are generally relatively expensive and conse-
quently access to them is largely restricted to centres with a special
interest in the area.
Measuring different capillaroscopic characteristics is fundamental
for research studies (see below). At present, manual or semi-manual
image analysis is time-consuming. To overcome this problem, software
for automated or semi-automated analysis of nailfold capillaroscopic
images is under evaluation (see “5. Scoring Systems”) [37–42]. These
computerized systems may, in the near future, offer additional benefits
such as the possibility of frame registration software [36], a much faster
analysis and extremely precise measurements [37–42].
4. Normality and abnormality
The NVC technique with 200× magnification, capturing at least
two adjacent fields of 1 mm in the middle of the nailfold finger, is the
gold standard capillaroscopic technique to perform nailfold capillaro-
scopy [1]. With NVC, images can be assessed qualitatively or (semi-)
quantitatively. In qualitative assessment “overall pattern recognition” is
being performed and images can be classified as “scleroderma pattern”
or not [22]. In quantitative assessment capillary characteristics can be
evaluated per unit of quantity (e.g. per linear mm). The following ca-
pillary characteristics can be evaluated when assessing an image: ca-
pillary density (number of capillaries), capillary morphology (shape of
individual capillaries), capillary dimension (width of the apical limb of
the capillary) and presence/absence of haemorrhages (see Table 2)
[22,43–45]. Each capillaroscopic characteristic has a “normal” range
(see Supplementary File 1). Certain characteristic capillaroscopic ab-
normalities or a combination of certain characteristic capillaroscopic
abnormalities are specific to the “scleroderma pattern”. More specifi-
cally the presence of giant capillaries (“giants”, i.e. capillaries with an
apical diameter ≥ 50 μm) or the combination of abnormal shapes with
an extremely lowered number of capillaries points to a “scleroderma
pattern” (see below) [22,46]. Besides the “scleroderma patterns”, a
variety of “non-scleroderma patterns” exists (i.e. stereotype “normal” or
“non-specific abnormalities”), which can occur in healthy individuals or
in CTDs other than SSc and may be a challenge to the non-experienced
capillaroscopist (see Table 2 and Fig. 4) [45].
Of note, different definitions have been used to describe abnormal
capillary morphology (e.g. “ramifications”, “neoangiogenesis” or
Fig. 3. Examples of capillaroscopic images obtained with a dermatoscope versus a nailfold videocapillaroscope.
The dermatoscope is a useful tool to detect capillary abnormalities, however uncertainty may arise when images are unclassifiable as a “scleroderma pattern” or not
(A1, B1) or when there are changes in capillary density or capillary dimension (C1). In these cases, it is opportune to move on to the nailfold videocapillaroscope,
which can give certainty (A2, B2, C2). Image D1 and D2 are pictures of easily recognisable “scleroderma patterns” both on the dermatoscope (D1) as well as on the
nailfold videocapillaroscope (D2).
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“meandering”) with low reliability [17,47]. To avoid confusion, the
EULAR Study Group on Microcirculation in Rheumatic Diseases
(EULAR SG MC/RD) has published by consensus a simple definition to
evaluate a single capillary as “(ab)normal”, adoptable to all rheumatic
diseases and capillaroscopic evaluations with the aim to have a stan-
dardized interpretation [48,49]. Capillaries with a “hairpin” shape,
(once or twice) crossing shape or tortuous shape (the afferent and ef-
ferent limb bend [= undulate] but do not cross) are defined as being
“normal”, on the condition that the tip of the capillary is convex (see
Table 2) [47–49]. All other shapes are defined as being “abnormal”.
This simple evaluation of single shapes of capillaries as “normal” or
“abnormal” has demonstrated excellent reliability when applied by
novices (n = 69) as well as by independent expert raters (n = 5) in a
multicentre international study [48,49].
4.1. A normal capillaroscopic pattern in primary Raynaud's phenomenon
and pathognomonic capillaroscopic patterns in secondary Raynaud's
phenomenon due to scleroderma spectrum disorders
In 1992 LeRoy et al. proposed criteria to distinguish primary from
secondary Raynaud's due to SSc and SDS disorders. These criteria are
easily applicable in daily practice [9]. In order to be classified as having
primary RP, a patient needs to fulfil the criterion of having a normal
capillaroscopy, conversely to patients with secondary RP due to SSc
who usually have a “scleroderma pattern” on capillaroscopy [9]. The
wide variety of images which are “non-scleroderma pattern” may be
challenging to the non-trained capillaroscopist as they consist of ste-
reotype normal images, more specifically a normal range capillary
density (≥ 7 capillaries per linear mm), a normal capillary morphology
(hairpin, tortuous or [once or twice] crossing shape), a normal capillary
dimension (width of limbs <20 μm) and absence of large confluent
bleedings, as well as “non-specific abnormalities” (see Fig. 4 and Sup-
plementary File 1) [22,50].
The same authors proposed criteria for secondary RP due to “early”
SSc. Patients with “early” SSc should have RP plus SSc-specific anti-
bodies (i.e. anti-CENP-B, anti-Th/To, anti-topo I or anti-RNAP III) and/
or a “scleroderma pattern” on nailfold capillaroscopy [51]. These cri-
teria have recently been validated by a 20-year prospective study on
patients with RP as sole presenting symptom [52]. Of those patients
with RP fulfilling both the criteria for “early” SSc, 65.9% developed
clinically overt SSc within 5 years and nearly 80% of them developed
clinically overt SSc after long term follow-up [52]. On the contrary,
only 1.8% of those patients having no SSc-specific antibodies and no
“scleroderma pattern” on nailfold capillaroscopy developed clinically
overt SSc after long term follow-up [52].
Even though specific definitions have been given by Maricq con-
cerning “abnormality” due to SDS disorders, confusion has arisen to the
non-expert rheumatologist concerning what “abnormality” refers to
[7]. In this way, abnormality in one of the capillaroscopic character-
istics has sometimes been incorrectly taken as “abnormality due to an
Fig. 3. (continued)
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SDS disorder” (see Table 2). To overcome this problem, the EULAR SG
MC/RD has published a “Fast Track algorithm” based on landmark
trials to discern a “scleroderma pattern”. This algorithm allows a ca-
pillaroscopist of any level of experience to differentiate a “scleroderma
pattern” from a “non-scleroderma pattern”, with a high reliability to the
principal expert [22].
Of note, in 2011, criteria for “very early” diagnosis of SSc (VEDOSS
criteria), which resulted from a three Delphi-rounds consensus study,
have been proposed [11]. These criteria also incorporate the presence
of “scleroderma pattern” on nailfold capillaroscopy as an important
criterion in addition to the presence of RP, puffy fingers, anti-nuclear
antibody (ANA) positivity and SSc-specific antibodies [11]. The vali-
dation process of these latter criteria is ongoing. A first step in the
validation of the VEDOSS criteria has been taken recently by the at-
testation of the fact that in the VEDOSS cohort the “early” scleroderma
pattern (with predominance of giants and no overt loss of capillaries
[see Fig. 5]) is the most prevalent pattern [53]. This lies in line with the
Koenig prospective study in which overt capillary loss did not occur
before the clinically overt disease had set in [52]. Of note, these criteria
are supported by a recent meta-analysis suggesting that “scleroderma
pattern” alone is a predictor for developing SSc in a 5 year-period (RR
11.81, 95%CI 4.07–34.25) and that the combination of a “scleroderma
pattern” and ANA positivity implies an even higher risk (RR 40.45,
95%CI 14.02–116.77) [54].
In addition, in the VEDOSS patients the “late” scleroderma pattern
does not occur [53]. This is conceivable, as in the clinically overt dis-
ease the “late” scleroderma pattern is associated with organ involve-
ment [55,56]. Most patients with clinically recognizable SSc on the
other hand, show a very characteristic combination of capillary ab-
normalities in the nailfold, which can easily be assessed through pattern
recognition.
Maricq et al. described the “scleroderma pattern” with the wide-
field technique [57]. This pathognomonic combination contains a
striking widening of all three segments of the capillary loop (arterial,
venous and intermediate), loss of capillaries and disorganization of the
nailfold capillary bed [57]. Many abnormal shapes, i.e. branched
“bushy” capillaries may also be observed [57]. These scleroderma-type
changes are also seen in SDS disorders, “other than” clinically re-
cognizable SSc, such as patients with RP without a definite diagnosis of
an associated disease, dermatomyositis (DM), mixed connective tissue
disease (MCTD) and undifferentiated connective tissue disease (UCTD)
[58]. Maricq et al. suggested that all these diseases may share some
common pathogenic factors and referred to these diseases as the family
of SDS disorders [58]. Maricq also defined these SDS patterns quanti-
tatively, in which a “definitely enlarged” capillary was attested to be
discriminant for SDS disorders [7]. More recently, Cutolo et al. quali-
tatively assessed the nailfolds of a SSc cohort with patients fulfilling the
ACR criteria for SSc with a newer technique (i.e. the NVC technique
with a 200× magnification) and subgraded the “scleroderma pattern”
into the “early”, “active” and “late” scleroderma pattern (see Table 2,
Fig. 5 and Supplementary File 2) [46].
Additionally, capillaroscopy has been incorporated in the 2013
ACR/EULAR criteria for the classification of SSc and in the assessment
and monitoring recommendations of RP in children [2,3,59].
4.2. “Non-specific abnormalities” in secondary Raynaud's phenomenon due
to connective tissue diseases “other than” scleroderma spectrum disorders
Opposite to the SDS disorders, the other connective tissue diseases,
such as systemic lupus erythematosus (SLE), Sjogren's syndrome etc., do
not have “unique” capillary patterns. Normal patterns and a variety of
“non-specific” capillary abnormalities have been observed, such as for
example, lowered capillary density, change in capillary dimension (e.g.
“elongated” capillaries, “widened” loops), prominence of the sub-
papillary plexus, haemorrhages, abnormal shapes (e.g. “bushy” capil-
laries, “bizarre” capillaries) [45,60]. These abnormalities by themselves
are not predictive of any defined condition and may be referred to as
“non-specific abnormalities”. The fact that “non-specific abnormalities”
Table 2
EULAR Study Group on Microcirculation in Rheumatic Diseases standardized capillaroscopy evaluation chart.
“Adapted from Smith V. et al., Fast Track algorithm: How to differentiate a ‘scleroderma pattern’ from a ‘non-scleroderma pattern’, Copyright (2019), with permission
from Elsevier.” [22]
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occur in primary RP may sometimes cause difficulties in differentiating
primary from secondary RP.
Generally, when abnormalities are isolated or uncommon, they may
represent variation of normal. When abnormalities are numerous or
when several abnormalities occur in one individual, they are indicative
of an underlying CTD. In this way, Andrade et al. registered a single
anomaly in 25% of healthy individuals, while 8% presented two types
and 1% showed three types of abnormalities [47].
However, specific abnormalities such as giants or the combination
of severe capillary loss with abnormal shapes are pathognomonic for
“scleroderma patterns” (see Table 2) [22].
Fig. 4. Examples of “Non-specific abnormalities”.
Technique: nailfold videocapillaroscopy with a 200× magnification. A vast variety of “non-scleroderma patterns” (stereotype “normal” or “non-specific abnorm-
alities” of capillaroscopic characteristics) may occur in a healthy population as well as in connective tissue diseases other than systemic sclerosis [22].
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5. Scoring systems
5.1. Qualitative, quantitative and semi-quantitative assessment of nailfold
capillaroscopy
In NVC qualitative assessment, “scleroderma patterns” (subgraded
as “early”, “active” and “late”) are able to distinguish between primary
and secondary RP and represent an essential and reliable parameter for
the early, as well as very early, diagnosis of SSc (see above)
[22,46,48,53,61,62]. Of note, recent introduction of capillaroscopic
assessment into the new 2013 ACR/EULAR classification criteria for SSc
reflects its pivotal role in the diagnosis of the disease [2,3,9].
In NVC quantitative assessment, capillaroscopic characteristics (i.e.
capillary density, capillary dimension, capillary morphology and pre-
sence/absence of haemorrhages) are standardly evaluated per unit of
quantity, e.g. per linear mm (see Table 2 and Supplementary File 1)
[22,43–45]. In this way for example, it has been attested recently that
significantly more abnormal shapes occur in SLE patients than in
healthy individuals [45]. Capillary density, as detected by NVC, is the
most reliable capillaroscopic parameter and has been used for the
prediction of disease progression as well as for the detection of effects of
treatment [17,63–67]. Capillary density has also been used for the
production of different predictive scoring systems in SSc, for example
the “Capillaroscopy Skin Ulcer Risk Index” (even though a history of
digital ulcers itself is still the strongest predictor for future development
of digital ulcers), the “Microangiopathy Evolution Score” (MES, see
below) and the simple day-to-day risk index to predict digital trophic
lesions in SSc [14,65,68]. Additionally, successful treatment in open
trial setting has been shown to reduce NVC alterations/scores in severe
SSc cases [69]. These findings support the importance of NVC scoring in
monitoring patients with SSc and suggest a putative role as an outcome
measure in SSc clinical trials [64,69]. In addition, very early quanti-
tative alterations of capillary diameter (i.e. dilations) have been found
to play a predictive role in the development of the “early” scleroderma
pattern [70]. Especially, the absence of a mean capillary diameter of
≥30 μm in patients with RP is predictive of non-occurrence of a sec-
ondary RP due to SSc. Interestingly, a correlation between qualitative
and quantitative NVC assessment and functional correlations (i.e.
peripheral blood flow changes) have also been clearly shown
[71–73,83].
Of note, scoring per linear mm of the individual parameters which
characterize the different qualitative NVC patterns has been attested to
be reliable for the following characteristics: capillary density, giants
(i.e. capillary dimension) and presence/absence of haemorrhages, but
not for “ramifications” (i.e. capillary morphology) [17]. Hence, the
EULAR SG MC/RD defined, for reasons of standardisation, a simple
definition to define abnormal shapes encompassing “ramifications”,
which has attested a high inter-rater reliability even in novice ca-
pillaroscopists [48,49,65].
Semi-quantitative and quantitative assessments have been proposed
by several groups for research aims. In this way, non-exhaustively, a
semi-quantitative rating scale to score microvascular parameters
(0 = no changes, 1 = ≤ 33% of capillary alterations/reduction,
2 = 33–66% of capillary alterations/reduction, 3 =≥ 66% of capillary
alterations/reduction, per linear mm) was found to be a sensitive tool to
quantify and to monitor the SSc microvascular damage within the 3
qualitative NVC patterns (i.e. “early”, “active” and “late”) [65].
This group also evaluated the MES (i.e. sum of three scores: capil-
lary loss, disorganization of the microvascular array and abnormal ca-
pillary shapes, defined in that study as “ramifications”) to assess the
progression of the vascular damage and attested the MES to increase
during the progression of SSc [65]. Of note, quantitative assessment, i.e.
standardly, rating of capillaroscopic characteristics (cfr. supra) per
linear mm, has been used in international studies [15].
More recently, a study approaching the question as to how many (and
which) fingers a clinician should routinely assess with NVC to detect ab-
normality (i.e. “giant capillaries” and “scleroderma pattern”), was pub-
lished. It was shown that the sensitivity to detect capillary abnormalities
increases as more fingers were examined: ranging from 31.7% to 46.6%
for only one finger (right middle and left ring finger respectively), 59.8%
for both ring fingers, 66.7% for a four-finger combination (both ring and
middle fingers) and 74.6% for the eight-finger gold standard. As such, the
authors concluded that all eight nailfold should be examined to accurately
detect capillary abnormality. However, it should be noted that in case of
time pressure, the best two-finger combination to detect capillary ab-
normalities is both ring fingers [74].
Fig. 5. Examples of “scleroderma pattern” images.
Technique: nailfold videocapillaroscopy with a 200× magnification.
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5.2. Automated NVC image analysis
The recent introduction of capillaroscopy in the 2013 ACR/EULAR
classification criteria for SSc contributed to an intense research on au-
tomated systems for NVC image analysis, which is currently ongoing.
Two recent systems merit attention. The Genoa system “AUTOCAPI”, is
a new fully automated method to determine in NVC images the absolute
number of capillaries in an operator selected segment of the nailfold,
which has attested to have a high reliability versus manual counting,
not only in difficult SSc image subsets, but also in the more regular
images obtained from healthy individuals and primary RP subject
subsets [41,75]. Integration of fully automated systems into the pre-
existing NVC imaging digital processing software present in every ca-
pillaroscopic computer may induce, according to the authors, a key
quantitative biomarker in videocapillaroscopy which may be much
easier, quicker and more standardized, as human interference in
counting within the operator selected segment is no longer required.
As it may provide a human independent follow-up of SSc patients,
fully automated systems for NVC image analysis may in the future be
useful in clinical daily practice as well as for clinical research purposes
including multicentre trials [75].
A group at the University of Manchester, UK, has developed a fully
automated system for extracting five quantitative markers of capillary
characteristics (including capillary density and apical width) [39], with
more recent incorporation of flow (i.e. red blood cell velocity) [76,77].
The system uses a layered machine learning approach, with no manual
steps between capturing an image and producing the quantitative data.
This state-of-the-art system has the potential of providing objective
outcome measures for monitoring in clinical studies, free from any
observer bias, with the further advantage of fast operator times (op-
erator time is only required for image acquisition, not for image ana-
lysis) and high performance characteristics to distinguish between
subjects with and without SSc [77].
6. Reliability
For any method to be adopted into clinical or research practice, it
has to be reliable: we must know the level of agreement between raters
when reporting the different parameters which are most commonly
used. These parameters (for NVC) include qualitative image grading (as
“scleroderma pattern” or “non-scleroderma pattern” and subgrading as
“early”, “active” or”late” according to Cutolo), semi-quantitative and
quantitative measures including capillary density, apical width, pre-
sence of giant capillaries, abnormal morphology and presence of hae-
morrhages [45,48,49].
Of note, the distal row of capillaries cannot always be clearly seen
(and therefore cannot always be evaluated): assessment of ‘evaluability’
varies between raters.
6.1. Reliability of image interpretation
Reliability to discern “scleroderma patterns” from “non-scleroderma
patterns” (image level of evaluation) has been attested by wide-field
and NVC to vary between good to excellent after training/consensus
between rheumatologists of any level of experience [21,22]. The re-
liability of subgrading “scleroderma patterns” varies more widely
though [17,21,78]. Evaluation of the reliability of individual ca-
pillaroscopic characteristics has been complicated by different studies
examining different parameters. Several studies have assessed the re-
liability of quantitative measures including capillary density or apical
diameter [16,18,20,21,36,79,80]. To overcome the plethora of defini-
tions concerning capillary morphology, a simple consensus definition
has been proposed by the EULAR SG MC/RD with high inter-rater re-
liability [48,49].
Reliability can be assessed at the patient level [16,17], at the whole
image level or at the capillary level [48,49], with a recent study
suggesting that reliability of qualitative grading scales was similar
when assessing one finger only (left 4th) or eight fingers [21].
These different studies examining intra- and inter-rater reliability
have given differing results, but several broad themes emerge:
First, inter-rater reliability to discern a “scleroderma pattern” from a
“non-scleroderma pattern” is good to excellent throughout studies in
rheumatologists with varying capillaroscopy training level [21,22].
Importantly, simple one-hour training to novices allows them to classify
an image as “scleroderma pattern” equally to a principal expert [22].
Logically, intra-rater reliability has been shown in several studies to be
higher than inter-rater reliability [18,19,21].
Second, reliability has been reported to improve with training
[21,78]. In this way, after consensus meetings, inter-rater agreement
improved for both the Cutolo and the Maricq subgrading scales [21].
Third, evaluability of images remains a major challenge and relates
in part to difficulties in obtaining high quality images from all patients
and also to different opinions between raters concerning what can be
defined as an evaluable nailfold. Evaluability varies across different
nailfold capillary parameters. For example, in a recent reliability study
involving 10 capillaroscopy experts, 73.0% of images from SSc patients
were evaluable in terms of capillary density and presence/absence of
giant capillaries, but only 46.2% in terms of image subgrading [19].
Subject to evaluability, certain capillaroscopic parameters (including,
from a recent study, capillary density and apical diameter [apical
“width”]) demonstrate high intra- and inter-rater reliability, hence,
having potential as outcome measures in longitudinal studies [17,19].
Fourth, reliability differs across different capillaroscopic parameters
[18,19,21]. By and large, number of capillaries is the most reliable
parameter [17].
6.2. Reliability of image acquisition
This has been much less studied than reliability of image inter-
pretation. Yet, reliability of image acquisition may be important to
outcome measure adoption as we need to know how much variability
between successive measures might relate to repeatability of the test.
Several factors could influence repeatability, for example if a different
section of the nailfold is captured at a second visit, results may be very
different [81].
A small number of reliability studies have incorporated image ac-
quisition as well as image interpretation [16,20,80,81]. A recent single
rater study examined intra-rater reliability for intra-visit (i.e. inter-
preting the same image twice) and inter-visit (i.e. imaging the same
finger twice, one week apart) [20]. Intra-visit reliability (intra-class
correlation coefficient [ICC]) was >0.90 for overall image grade, vessel
density and apex diameter (limb “width”) and inter-visit reliability was
also good for overall grade and apex diameter (limb “width”) (ICC 0.90
and 0.79 respectively). These results suggest that at least with a single
rater, both image analysis and acquisition are reliable.
7. Conclusions on standardisation
With the recent incorporation of capillaroscopy in the 2013 ACR/
EULAR classification criteria for SSc together with its assessed role in
monitoring the progression of the disease [2,3,82], its increasing use by
a variety of physicians internationally in daily practice as well as in
research context and its promising results concerning predicting disease
progression and monitoring of treatment effects, the achievement of
standardisation in capillaroscopic image acquisition and analysis
worldwide seems extremely important. This paper provides a consensus
view from capillaroscopy experts concerning image acquisition and
analysis, different capillaroscopic techniques, normal and abnormal
capillaroscopic characteristics and their meaning, scoring systems and
reliability of image acquisition and interpretation:
(1) The nailfold videocapillaroscopic technique with 200×
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magnification, capturing at least two adjacent fields of a linear
millimetre in the middle of the finger, is the gold standard ca-
pillaroscopic technique to perform nailfold capillaroscopy.
However, dermatoscopy, USB microscopy and ophthalmoscopy
may be used as a screening tool.
(2) The following capillaroscopic characteristics are evaluated in a
standardized manner when quantitatively assessing a capillaro-
scopic image: capillary density, capillary dimension, presence/ab-
sence of abnormal shapes and presence/absence of haemorrhages.
(3) In healthy individuals or in patients with CTDs other than SSc, both
stereotype “normal” capillaroscopic characteristics, as well as a
variety of capillaroscopic changes (i.e. “non-specific abnormal-
ities”) may be present. In SSc, specific abnormalities (i.e. the
“scleroderma pattern”) may be present.
(4) Inter-rater reliability to discern a “scleroderma pattern” from a
“non-scleroderma pattern” is good to excellent throughout studies
in rheumatologists with different capillaroscopy training levels.
Subgrading of the “scleroderma pattern” into “early”, “active” or
“late” improves with training.
(5) Research concerning automated measurement of capillaroscopic
characteristics is quickly evolving. Automated measurement holds
promise as clinical trial outcome measure.
Based on capillaroscopic characteristics (capillary density, capillary
dimension, abnormal capillary morphology and presence/absence of
haemorrhages), the assessor can deduct whether an image has changes
specific to the “scleroderma pattern” as they occur in scleroderma
spectrum diseases (i.e. presence of giant capillaries such as in the
“early” or “active” scleroderma pattern, or presence of severe lowered
density combined with abnormal shapes, such as in the “late” scler-
oderma pattern) or if the image is “normal” or has “non-specific” ab-
normalities as can occur in the healthy population, in primary RP or in
connective tissue diseases other than systemic sclerosis [1–7].
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